Triantafillos Liloglou is a Lecturer at the Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK, and a Biomarkers Group Leader in the University's Cancer Research Centre. He received the B.S. degree with honors in biology from the Aristotle University of Thessaloniki, Thessaloniki, Greece, in 1988, followed by the Ph.D. degree in molecular oncology from the Medical School of the University of Crete, Rethymno, Greece. His postdoctoral research has focused on the molecular pathogenesis of human respiratory cancers. During his early postdoctoral years, he investigated the role of genomic instability and involvement of p53 inactivation in tumor development and progression. In 1998, he joined the Liverpool Lung Project, one of the largest population studies for lung cancer. His research group works on the development of assays based on cancer-specific genetic and epigenetic abnormalities and validation of these assays to measure their potential impact on the clinical management of respiratory cancer: early detection, prediction of relapse, and therapeutic stratification. In the last decade, he particularly focused his research on epigenetics and DNA methylation. He was among the pioneers in using pyrosequencing for DNA methylation detection and has currently developed a novel method in collaboration with an industrial partner. His group is studying the epigenetic deregulation in lung cancer and develops biomarkers for early lung cancer detection utilizing samples such as sputum, plasma, oral scrapes, and bronchial washings. Dr. Liloglou is collaborating with multiple academic and industrial partners in various aspects of respiratory cancer biology and biomarker development. Currently, the Liverpool Lung Project aims to undertake very soon prospective biomarker trials at both hospital and primary care levels.
Biography Updated on 23 October 2013